Somewhere in a sports medicine clinic right now, a patient is being quoted several thousand dollars out of pocket for an injection that promises to regenerate damaged tissue. The pitch sounds compelling. The evidence, depending on what is being injected and where, may be anything but. Altamash Raja, a physical medicine and rehabilitation physician with training in musculoskeletal ultrasound, describes the current landscape of orthobiologics plainly: the evidence is tissue-specific, the formulations vary, and the hype, in many cases, has run well ahead of what the data actually shows.
Platelet-rich plasma, or PRP, is the treatment with the strongest existing body of evidence, and Raja points to knee osteoarthritis as its most promising application. Tendon injuries present a more complicated picture. Outcomes differ depending on the specific region being treated, and because PRP formulations are not standardized across clinics, two patients receiving what they are told is the same procedure may not be receiving anything close to the same thing. Cell-based therapies derived from bone marrow or adipose tissue occupy even shakier ground. "The evidence is largely preliminary, and the hype exceeds what the actual data shows," Raja said. "That's where patients end up paying for hope, especially when someone promises to regrow tissue."
The question of how physicians decide which injections are worth offering is inseparable from the question of how they are diagnosing the problem in the first place. Raja uses in-office ultrasound not as a standalone imaging tool but as what he calls an extension of the physical exam. Its defining advantage is motion. An MRI captures a still image; ultrasound allows him to observe a nerve or tendon while the patient moves into the exact position that reproduces their symptoms. For conditions involving nerves compressed only in certain positions, he argues it may be the most diagnostically useful imaging available. Once the problematic position is identified, the same probe guides the injection. The limitation, he is quick to note, is operator dependency. "Results depend on the operator's training," he said, which is why the technology remains underused despite its clinical value.
Running beneath both of these questions, the evidence for injections and the tools used to guide them, is a tension Raja sees in how medicine approaches recovery more broadly. He draws a clear distinction between rehabilitation and simple rest, describing rehabilitation as exercise built on strength and conditioning principles, not a passive waiting period. His criticism of standard medical training is direct: "We restrict exercise too often, even when it delays recovery." What he teaches residents instead is an approach that respects tissue biology while still applying training principles, one that gives patients independence and, as he frames it, more options in life.
That framing, rehabilitation as a means of expanding patient autonomy rather than simply managing an injury, is what connects his skepticism about oversold injections to his insistence on movement-based recovery. A procedure that promises tissue regrowth without a rehabilitation foundation may generate a bill and a period of hope. Whether it changes what a patient can do with their body is a different question, and by Raja's account, one that too few clinics are asking before the needle goes in.
